| Literature DB >> 34692960 |
Drake G LeBrun1, Tony S Shen1, Patawut Bovonratwet1, Rachelle Morgenstern1, Edwin P Su1.
Abstract
BACKGROUND: Hip resurfacing arthroplasty (HRA) and total hip arthroplasty (THA) are two treatment options for end-stage degenerative hip conditions. The objective of this single-center retrospective cohort study was to compare implant survival and patient-reported outcomes (PROs) in young patients (≤35 years) who underwent HRA or THA.Entities:
Keywords: HOOS-JR; Hip resurfacing; Total hip arthroplasty; UCLA activity score; mHHS
Year: 2021 PMID: 34692960 PMCID: PMC8516816 DOI: 10.1016/j.artd.2021.09.004
Source DB: PubMed Journal: Arthroplast Today ISSN: 2352-3441
Demographic and clinical data of extremely young (≤35) patients undergoing primary total hip arthroplasty or hip resurfacing arthroplasty.
| Variable | Total sample | Hip resurfacing | Total hip arthroplasty | ||||
|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | ||
| Patients | 91 | 65 | 26 | ||||
| Hips | 109 | 76 | 33 | ||||
| Female | 34 | 31% | 8 | 11% | 26 | 79% | <.001 |
| Median age (y) (IQR) | 31.4 (25.7, 33.6) | 32.2 (27.7, 33.9) | 27.9 (22.6, 32.3) | .004 | |||
| Median BMI (kg/m2) (IQR) | 25.8 (22.9, 29.0) | 26.2 (24.3, 29.6) | 23.3 (20.6, 27.1) | .005 | |||
| Obese (BMI > 30 kg/m2) | 22 | 20% | 16 | 21% | 6 | 18% | .829 |
| Diagnosis | <.001 | ||||||
| Avascular necrosis | 37 | 34% | 20 | 26% | 17 | 52% | |
| Primary osteoarthritis | 19 | 17% | 17 | 22% | 2 | 6% | |
| Femoracetabular impingement | 19 | 17% | 19 | 25% | 0 | 0% | |
| Developmental dysplasia of the hip | 15 | 14% | 7 | 9% | 8 | 24% | |
| Posttraumatic arthritis | 8 | 7% | 6 | 8% | 2 | 6% | |
| Inflammatory arthritis | 8 | 7% | 4 | 5% | 4 | 12% | |
| Tumor | 3 | 3% | 3 | 4% | 0 | 0% | |
| Laterality | .756 | ||||||
| Left | 52 | 48% | 37 | 49% | 15 | 45% | |
| Right | 57 | 52% | 39 | 51% | 18 | 55% | |
BMI, body mass index; IQR, interquartile range.
Patients (n = 4) with a history of slipped capital femoral epiphysis who all underwent hip resurfacing.
Bearing surfaces and implants used in the study sample.
| Variable | Hip resurfacing, n = 76 hips | Total hip arthroplasty, n = 33 hips | |||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Bearing surfaces | <.001 | ||||
| Ceramic-on-ceramic | 0 | 0% | 11 | 33% | |
| Ceramic-on-polyethylene | 0 | 0% | 20 | 61% | |
| Metal-on-metal | 76 | 100% | 2 | 6% | |
| Femoral implant | |||||
| Birmingham hip resurfacing | 76 | 100% | 0 | 0% | |
| Smith + Nephew Anthology | 0 | 0% | 28 | 85% | |
| Depuy Synthes S-ROM | 0 | 0% | 2 | 6% | |
| MicroPort Profemur | 0 | 0% | 2 | 6% | |
| Stryker Secur-fit | 0 | 0% | 1 | 3% | |
| Acetabular implant | |||||
| Birmingham hip resurfacing | 76 | 100% | 1 | 3% | |
| Smith + Nephew R3 | 0 | 0% | 29 | 88% | |
| MicroPort Lineage | 0 | 0% | 1 | 3% | |
| Depuy Synthes Pinnacle | 0 | 0% | 1 | 3% | |
| Stryker Trident | 0 | 0% | 1 | 3% | |
| Median cup size (mm) (IQR) | 56 (52, 58) | 50 (48, 52) | <.001 | ||
| Median head size (mm) (IQR) | 50 (46, 52) | 32 (28, 32) | <.001 | ||
IQR, interquartile range.
Figure 1Kaplan-Meier plot comparing 5-year all-cause revision between patients undergoing hip resurfacing arthroplasty or total hip arthroplasty. P-value based on the log-rank test. Shading indicates 95% confidence intervals for each cohort. hra, hip resurfacing arthroplasty; tha, total hip arthroplasty.
Patient-reported outcome measures of extremely young (≤35) patients undergoing primary total hip arthroplasty or hip resurfacing arthroplasty at minimum 2-year follow-up.
| Variable | Total sample | Hip resurfacing | Total hip arthroplasty | ||||
|---|---|---|---|---|---|---|---|
| n = 109 | n = 76 | n = 33 | |||||
| Mean | SD | Mean | SD | Mean | SD | ||
| UCLA | |||||||
| Preop | 4.6 | 2.3 | 5.2 | 2.4 | 3.2 | 1.1 | |
| Postop | 8.2 | 1.8 | 8.4 | 1.6 | 6.7 | 2.3 | |
| Difference | 3.4 | 2.3 | 3.5 | 2.3 | 2.7 | 2.3 | .397 |
| mHHS | |||||||
| Preop | 56.2 | 13.4 | 58.9 | 14.3 | 50.2 | 8.6 | |
| Postop | 92.2 | 10.5 | 94.4 | 8.2 | 86.7 | 13.5 | |
| Difference | 35.7 | 14.7 | 35.6 | 14.4 | 35.9 | 15.6 | .930 |
| HOOS-JR | |||||||
| Preop | 60.1 | 15.0 | 64.0 | 12.6 | 52.7 | 16.7 | |
| Postop | 91.7 | 12.8 | 96.5 | 6.7 | 80.6 | 16.5 | |
| Difference | 29.7 | 17.8 | 31.7 | 15.0 | 26.0 | 22.2 | .366 |
SD, standard deviation.
Values are reported as means (standard deviations). P-values are reported according to the t-test or Wilcoxon rank-sum test depending on whether the data were parametric or nonparametric, respectively. Statistically significant values are bolded.